Hospital La Candelaria in Tenerife Tops Regional Healthcare Excellence Rankings as Spain Expands Access to Advanced Treatments
Hospital La Candelaria leads Canary Islands' healthcare excellence rankings as Spain broadens public funding for innovative treatments in cancer, hemophilia, and other severe diseases.
- • Hospital Universitario Nuestra Señora de Candelaria ranked top in Canary Islands' Índice de Excelencia Hospitalaria for second year.
- • Hospital improvements include new Emergency building, Palliative Care Unit, operating room renovations, and HIFU treatment for tremors.
- • Hospital is a national reference for liver transplants and recognized for research and specialized care.
- • Spain's Ministry of Health proposed public funding for new drugs addressing prostate cancer, hemophilia, lymphoma, hypertension, and inflammatory diseases.
Key details
The Hospital Universitario Nuestra Señora de Candelaria in Tenerife has been recognized once again as the highest-rated hospital in the Canary Islands under the Índice de Excelencia Hospitalaria, according to a recent study conducted by the Instituto Coordenadas de Gobernanza y Economía Aplicada. This marks the second consecutive year that the hospital has led the regional ranking, which is informed by the evaluations of 2,100 healthcare professionals across Spain. The assessment covers both public and private hospitals, focusing on quality of care, innovation, and service improvements.
Throughout 2025, Hospital La Candelaria implemented several significant enhancements, including the inauguration of a new Emergency building, the launch of a Palliative Care Unit at the Hospital del Sur, renovations to the operating rooms at Hospital de Ofra, and adoption of the innovative High-Intensity Focused Ultrasound (HIFU) technique to treat essential tremors. The hospital also hosted its first Open Doors Day for the Research Unit, highlighting its commitment to medical innovation and research.
Notably, the hospital has earned multiple recognitions for its specialized care, serving as a national reference center for liver transplants and receiving accolades in Palliative Care, Cardiology, Pneumonia, and Pediatrics. Its research activities were acknowledged at key events such as the SEDAR Congress and the II Canarias Awards for Health Sciences and Biomedical Research.
On the national policy front, in December 2025, the Spanish Ministry of Health announced new drug coverages to expand treatment options for critical conditions. The Interministerial Commission on Drug Prices proposed funding for Illuccix, a PET scan agent enhancing prostate cancer detection; Hympavzi, for routine prophylaxis in severe hemophilia patients; Breyanzi, a therapy targeting aggressive lymphomas; Imbarix, a combination medication for hypertension; and Gobivaz, the first biosimilar for golimumab, treating multiple inflammatory conditions. These advancements signal Spain's ongoing efforts to integrate cutting-edge medical therapies into public healthcare, complementing the excellence demonstrated by institutions like Hospital La Candelaria.
Together, these developments underscore Spain's multifaceted progress in healthcare excellence—combining top-tier hospital services and expanded access to innovative pharmaceutical treatments—to improve patient outcomes nationwide.
This article was synthesized and translated from native language sources to provide English-speaking readers with local perspectives.
